Light activated therapy shows promise against leukemia
Four of five patients with cutaneous T cell leukemia who received a light activated extracorporeal therapy using methoxypsoralen and ultraviolet light resumed normal activity with no toxic side effects. One patient with advanced disease did not respond. The treatment, developed at Columbia Presbyterian Medical Center, is not yet available to the public and may take years to reach general use.